Review

Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population

Figure 1 from The Lancet Oncology — Figure 1Turnbull et al.

The Lancet Oncology

The paper

Clare Turnbull, Sandra Perdomo, Susan Domchek,

William David Foulkes, Paul Pharoah, Patrícia Ashton‐Prolla, Bhawna Sirohi, Joaquı́n Mateo, Hilary A. Robbins, Richard Sullivan, Mark Lawler,

Raffaella Casolino

Royal Marsden NHS Foundation Trust · University of Glasgow

The Lancet Oncology · 25 Sep 2026

doi.org/10.1016/s1470-2045(26)00390-6 PubMed 42790443

Plasma proteomics reveals pre-diagnostic markers for 25 cancers
medRxiv · 4 Oct 2026
Prescription drugs tied to digestive cancer risk in older adults
Cancer Epidemiology, Biomarkers & Prevention · 4 Oct 2026
Pre-existing dementia tied to higher cancer mortality
The Lancet Healthy Longevity · 4 Oct 2026
Partial Y chromosome loss alters transcription in cancer cells
Communications Biology · 4 Oct 2026